MX367346B - Metodo para incrementar la expresion de antigenos. - Google Patents

Metodo para incrementar la expresion de antigenos.

Info

Publication number
MX367346B
MX367346B MX2015016832A MX2015016832A MX367346B MX 367346 B MX367346 B MX 367346B MX 2015016832 A MX2015016832 A MX 2015016832A MX 2015016832 A MX2015016832 A MX 2015016832A MX 367346 B MX367346 B MX 367346B
Authority
MX
Mexico
Prior art keywords
antigens
antigen expression
upregulating
radioimmunoconjugates
relates
Prior art date
Application number
MX2015016832A
Other languages
English (en)
Other versions
MX2015016832A (es
Inventor
H Larsen Roy
Repetto-Llamazares Ada
Original Assignee
Nordic Nanovector Asa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nordic Nanovector Asa filed Critical Nordic Nanovector Asa
Publication of MX2015016832A publication Critical patent/MX2015016832A/es
Publication of MX367346B publication Critical patent/MX367346B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a radioinmunoconjugados que son capaces de incrementar la expresión de uno o más antígenos. El incremento de antígenos pueden ser los antígenos contra los que están dirigidos los radioinmunoconjugados o diferentes antígenos expresados en las mismas células. La presente invención también se refiere a métodos para tratar el cáncer y las enfermedades y trastornos del sistema inmune mediante la utilización de este aumento de la expresión de antígenos.
MX2015016832A 2013-06-07 2014-06-06 Metodo para incrementar la expresion de antigenos. MX367346B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201370313 2013-06-07
PCT/EP2014/061824 WO2014195460A1 (en) 2013-06-07 2014-06-06 Method for upregulating antigen expression

Publications (2)

Publication Number Publication Date
MX2015016832A MX2015016832A (es) 2016-05-31
MX367346B true MX367346B (es) 2019-08-15

Family

ID=50896309

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015016832A MX367346B (es) 2013-06-07 2014-06-06 Metodo para incrementar la expresion de antigenos.

Country Status (19)

Country Link
US (2) US20160101199A1 (es)
EP (2) EP3003402B1 (es)
JP (2) JP6335284B2 (es)
KR (1) KR102033819B1 (es)
CN (2) CN108939065A (es)
AU (1) AU2014276827B2 (es)
BR (1) BR112015030457A2 (es)
CA (1) CA2911962A1 (es)
DK (2) DK3003402T3 (es)
ES (2) ES2741643T3 (es)
HK (1) HK1256497B (es)
IL (1) IL242892A (es)
MX (1) MX367346B (es)
NO (1) NO3003402T3 (es)
PH (1) PH12015502713B1 (es)
RU (1) RU2681953C2 (es)
SG (1) SG11201510035UA (es)
UA (1) UA119443C2 (es)
WO (1) WO2014195460A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2546674Y2 (ja) 1991-02-27 1997-09-03 エヌオーケー株式会社 中空糸膜の交差状糸束製造装置
MX338932B (es) 2010-03-12 2016-05-06 Immunogen Inc Moleculas de union cd37 y sus inmunoconjugados.
DK3261681T3 (da) * 2015-02-26 2020-04-27 Sciencons AS Radiofarmaceutiske opløsninger med fordelagtige egenskaber
UA125496C2 (uk) 2015-06-08 2022-04-13 Дебіофарм Інтернаціонал, С.А. Спосіб лікування пацієнта з в-клітинним раком імунокон’югатом, який зв’язується з cd37 разом з антитілом, що зв'язується з cd20
AU2016316758B2 (en) 2015-08-28 2023-02-02 Debiopharm International, S.A. Antibodies and assays for detection of CD37
WO2018083633A1 (en) 2016-11-02 2018-05-11 Debiopharm International, S.A. Methods for improving anti-cd37 immunoconjugate therapy
JP7370958B2 (ja) * 2017-07-31 2023-10-30 アクティニウム ファーマシューティカルズ インコーポレイテッド 血液悪性腫瘍の治療
WO2019094931A1 (en) * 2017-11-10 2019-05-16 Actinium Pharmaceuticals, Inc. Combination therapy for treatment of a hematological disease
EP3713607A1 (en) * 2017-11-22 2020-09-30 Nordic Nanovector ASA Radioimmunoconjugates in combination with other drugs as treatment against nhl
CA3101790A1 (en) 2018-05-30 2019-12-05 Debiopharm International, S.A. Anti-cd37 immunoconjugate dosing regimens
CN117285631A (zh) * 2023-11-24 2023-12-26 原子高科股份有限公司 用于放射性免疫治疗的Lu-177标记MUC1抗体

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
PL195870B1 (pl) * 1998-08-11 2007-11-30 Biogen Idec Inc Zastosowanie przeciwciała anty-CD20, zastosowanieznakowanego radioaktywnie przeciwciała anty-CD20,zastosowanie przeciwciała anty-CD20 do przygotowania leku zwierającego przeciwciało i chemioterapięoraz zastosowanie przeciwciała anty-CD20 do przygotowania leku zawierającego przeciwciało i szpik kostny
AU2003209446B2 (en) * 2002-03-01 2008-09-25 Immunomedics, Inc. Bispecific antibody point mutations for enhancing rate of clearance
EP2295080A3 (en) * 2005-07-25 2011-06-22 Emergent Product Development Seattle, LLC B-cell reduction using CD37-specific and CD20-specific binding molecules
TWI409079B (zh) * 2009-08-14 2013-09-21 Roche Glycart Ag 非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法
NO331080B1 (no) * 2010-01-29 2011-09-26 Nordic Nanovector As Radioimmunkonjugater, farmasøytiske sammensetninger og kit omfattende det samme og anvendelse derav
KR20140103140A (ko) * 2011-12-13 2014-08-25 노르딕 나노벡터 에이에스 치료용 키메릭 항-cd37 항체 hh1
JP2015517512A (ja) * 2012-05-16 2015-06-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｄ３７抗体の更なる薬剤との併用

Also Published As

Publication number Publication date
US20190008989A1 (en) 2019-01-10
JP2018150323A (ja) 2018-09-27
EP3332813B1 (en) 2019-05-29
AU2014276827A1 (en) 2016-01-28
DK3003402T3 (en) 2018-04-16
RU2015154447A (ru) 2017-07-17
CN105451781A (zh) 2016-03-30
HK1256497B (en) 2020-06-05
RU2681953C2 (ru) 2019-03-14
UA119443C2 (uk) 2019-06-25
IL242892A (en) 2017-07-31
CN108939065A (zh) 2018-12-07
MX2015016832A (es) 2016-05-31
AU2014276827B2 (en) 2018-11-15
NO3003402T3 (es) 2018-06-16
WO2014195460A1 (en) 2014-12-11
JP6335284B2 (ja) 2018-05-30
US10646599B2 (en) 2020-05-12
ES2662964T3 (es) 2018-04-10
US20160101199A1 (en) 2016-04-14
ES2741643T3 (es) 2020-02-11
EP3003402B1 (en) 2018-01-17
KR20160039178A (ko) 2016-04-08
HK1217438A1 (en) 2017-01-13
JP2016520640A (ja) 2016-07-14
DK3332813T3 (da) 2019-06-24
EP3003402A1 (en) 2016-04-13
JP6590985B2 (ja) 2019-10-16
CA2911962A1 (en) 2014-12-11
SG11201510035UA (en) 2016-01-28
PH12015502713B1 (en) 2020-02-28
KR102033819B1 (ko) 2019-10-17
BR112015030457A2 (pt) 2017-08-22
RU2015154447A3 (es) 2018-03-07
EP3332813A1 (en) 2018-06-13
PH12015502713A1 (en) 2016-03-14
CN105451781B (zh) 2018-07-27

Similar Documents

Publication Publication Date Title
PH12015502713A1 (en) Method for upregulating antigen expression
SA519401522B1 (ar) Lag-3 أجـسـام مـضـادة لـ وتـركـيـبـات
MX2021002728A (es) Combinacion de anticuerpos anti-gen 3 de la activacion del linfoncito (lag-3) y anticuerpos anti-muerte celular programada 1 (pd-1) para usarse en el tratamiento de tumores.
PH12018500380A1 (en) Anti-dll3 antibody drug conjugates and methods of use
TN2015000396A1 (en) Antibody drug conjugates
MX2023000889A (es) Anticuerpos contra bcma y su uso para tratar el cancer y los trastornos inmunitarios.
PH12017500002A1 (en) Anti-cdh6 antibody drug conjugates
MX2015012122A (es) Conjugados de anticuerpo-farmaco y los anticuerpos correspondientes.
MX2016002826A (es) Anticuerpos anti-b7-h1 para tratar tumores.
MX389684B (es) Anticuerpos anti tigit.
PH12015501846A1 (en) Novel antibody conjugates and uses thereof
MX2020002694A (es) Moleculas de anticuerpo que se unen a tim-3 y usos de las mismas.
EA201400625A1 (ru) Антитела против pd-l1 и их применение
PH12017500406A1 (en) Novel anti-mfi2 antibodies and methods of use
GEP20227343B (en) Anti-lag3 antibodies and antigen-binding fragments
MX377714B (es) Composiciones que comprenden una combinación de un antagonista de vegf y un anticuerpo anti-ctla-a.
IN2014DN05885A (es)
EA201591791A1 (ru) Антитела pac1 человека
EA201890747A1 (ru) Способы лечения воспалительных заболеваний
MX2018006249A (es) Nuevos anticuerpos anti-emr2 y metodos de uso.
NZ723884A (en) Methods of treating alzheimer’s disease
MX2017001138A (es) Metodo.
MX2015011518A (es) Agentes de enlace de met y usos de los mismos.
MX2017011991A (es) Terapia virica con una combinacion de anticuerpos.
MX2018007817A (es) Nuevos anticuerpos anti-mmp16 y metodos para su uso.

Legal Events

Date Code Title Description
FG Grant or registration